VTGN — Vistagen Therapeutics Share News
0.000.00%
Last trade - 00:00- $7.97m
- -$23.76m
- $1.27m
Brief: Vistagen Regains Full Compliance With Nasdaq Listing Requirements
Brief: Vistagen Announces Results Of Successful US Phase 1 Study Of Itruvone, Enabling US Phase 2B Development For Treatment Of Major Depressive Disorder
Vistagen Therapeutics Inc expected to post a loss of $1.50 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Rio Tinto, BurgerFi International, Aclaris Therapeutics
U.S. STOCKS ON THE MOVE-Comerica, copper miners, Journey Medical
VistaGen expects to receive European patent for migraine drug, shares rise
Brief: Vistagen Announces Positive Results From Exploratory Phase 2A Study Of Ph80 In Women Diagnosed With Menopausal Hot Flashes
Brief: Vistagen Announces Stockholder-Approved Reverse Stock Split
Brief: Vistagen Awarded Mental Health America's Platinum Bell Seal For Workplace Mental Health
U.S. STOCKS ON THE MOVE-AMC, Alphabet, Levi Strauss
Brief: VistaGen Receives New European Patent For AV-101
Brief: FDA Provides Positive Feedback To Vistagen Regarding Use Of The Liebowitz Social Anxiety Scale (Lsas) As An Endpoint In Phase 3 Development Of Fasedienol (Ph94b) For Treatment Of Social Anxiety Disorder
U.S. STOCKS ON THE MOVE-Nike, Nvidia, Boeing
U.S. STOCKS ON THE MOVE-Carvana, Vistagen, Shoe Carnival
Vistagen rises as nasal spray for anxiety found safe in late-stage study
Brief: Vistagen Announces Completion Of Last Patient, Last Visit In Phase 1 Clinical Trial Of Itruvone
Brief: Vistagen Therapeutics - On March 7, Received Letter From Nasdaq That Co Granted Until Sept 5, 2023 To Regain Compliance With Min Bid Price Requirement
Brief: Vistagen Therapeutics Inc Files For Offering Of Up To 12.4 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
VistaGen Therapeutics Inc reports results for the quarter ended in December - Earnings Summary